Skip to main content
. 2018 Jul 25;3(5):e000332. doi: 10.1136/esmoopen-2018-000332

Figure 2.

Figure 2

Kaplan-Meier curves of OS by dose of nivolumab for (A) all patients (n=47), (B) PD-L1-positive patients (n=13) and (C) PD-L1-negative or unknown patients (n=34). mOS, median overall survival; nr, not reached; PD-L1, programmed death-ligand 1; OS, overall survival.